What happened with NVST today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Envista Holdings Corporation supplies dentists with products used to replace missing teeth, straighten teeth and diagnose dental conditions. Implant and orthodontic products generate most of its sales, including NobelActive implants and Spark clear aligners. It sells these products mainly directly to the professionals who use them.
The company also supplies dental practices with imaging equipment, including the DEXIS OP 3D system, and everyday treatment supplies, mainly through distributors. Across the business, consumables, services and spare parts account for the large majority of sales rather than equipment. Henry Schein is its largest customer and an important distribution partner, but Envista has no current master distribution agreement with it in the United States and Canada, and purchases are not guaranteed.
Demand for some treatments depends on patients’ willingness and ability to pay out of pocket for elective dental care. Most Envista products are regulated medical devices, and FDA clearances permit marketing only for their labeled uses.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Envista's results hinge on demand for dental procedures and competition in implants and orthodontics, making Straumann an important rival to watch even though it is absent from this list.
Dentsply Sirona competes with Envista for dental professionals' spending on dental products, technology and implant systems, so both are exposed to treatment volumes and dentists' purchasing. Its dental equipment and consumables business is worth watching for signs of that spending.
Align Technology competes with Envista's Spark aligners and orthodontic products by selling Invisalign clear aligners to the same dental professionals. Watch its clear-aligner revenue for a read on treatment demand and rivalry: that segment accounted for approximately 80% of its worldwide net revenues in 2025.
Envista depends on Henry Schein as a buyer and dental-supply distributor: it accounted for approximately 12% of Envista's sales in 2025, while also competing in implants and materials used to regenerate dental tissue. Watch its sales of supplies and equipment to dental practices for a read on purchasing demand that matters to Envista.
Solventum competes with Envista for dental professionals' purchases of brackets, aligners, restorative cements and bonding agents. Watch its Dental Solutions sales rather than overall results for the closer comparison: dental products accounted for only 16.2% of Solventum's total sales in 2025.
Align Technology Inc earningsALGN
Align Technology’s report will show how dentists and patients are responding to clear aligners, giving a direct market read for Envista’s competing Spark system.
Watch Align Technology’s clear-aligner revenue. Resilient revenue would show that dentists and patients are still choosing this treatment, supporting demand for Envista’s Spark aligners; weaker revenue would point to softer category demand or tougher rivalry, making orders harder for Envista to win.
Fed Interest Rate Decision
Envista’s Fed interest-rate decision tracks the cost of borrowing across the economy, which can change interest expense on its variable-rate debt and leave less or more of its dental-product sales as profit.
Expected4.0%Last release4.0%
If it comes in above expectations
If the Fed sets rates above expectations, Envista may pay more interest on debt that reprices, leaving less profit from sales of implants, aligners, imaging equipment and other dental products.
If it comes in below expectations
If the Fed sets rates below expectations, lower borrowing costs may reduce interest expense on debt that reprices, leaving Envista more profit from sales of its dental products.
Henry Schein Inc earningsHSIC
Henry Schein’s report will show dental practices’ purchases of supplies and equipment; it is both a major Envista customer and a distributor of its products.
Watch Henry Schein’s sales of supplies and equipment to dental practices, bearing in mind that its own inventory changes can also alter purchases from Envista. Stronger practice sales would support end-customer demand through Envista’s channel; weaker sales could mean practices are buying less or that channel inventory is shifting, so they would not by themselves prove that treatment demand has fallen.
Envista Holdings Corporation earningsThis company
Envista’s report will show whether sales of its dental products are growing through customer demand and pricing, rather than mainly through the timing of clear-aligner revenue recognition.
Read core sales growth alongside gross margin, and account for the timing effect from clear-aligner revenue recognition. If sales still grow beyond that effect and gross margin holds, customer demand and pricing are supporting the business; if growth relies mainly on the timing effect while margin weakens, the sales increase is not translating into firmer profitability.
DENTSPLY SIRONA Inc. earningsXRAY
Dentsply Sirona’s report will show whether dental practices are buying equipment and consumables, providing a read on demand for Envista’s overlapping products.
Watch Dentsply Sirona’s dental equipment and consumables sales. Resilient sales would show that practices are still buying these products, supporting demand for Envista’s overlapping businesses; weaker sales would suggest tighter practice spending and greater pressure on Envista’s equipment and consumables sales.
